Study of AS1404 With Docetaxel in Patients With Hormone Refractory Metastatic Prostate Cancer
The purpose of this trial is to confirm a safe dose of AS1404, to be given with docetaxel, and to see whether adding AS1404 and docetaxel together improves the outcome of the treatment, when compared to docetaxel alone.
Prostate Cancer
DRUG: AS1404 (DMXAA)
Laboratory safety|Adverse event monitoring|Electrocardiogram (EKG)|Ophthalmic assessments|Tumor assessment|Time to progression and survival time|Prostate-specific antigen (PSA)|Pharmacokinetic sampling
The overall aim of this study is to determine the safety, tolerability and efficacy of AS1404 in combination with docetaxel in patients with hormone refractory metastatic prostate cancer.